Journal of Infection
2019
Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe (Article) (Open Access)
Bai X. ,
Borrow R.* ,
Bukovski S. ,
Caugant D.A. ,
Culic D. ,
Delic S. ,
Dinleyici E.C. ,
Eloshvili M. ,
Erdősi T. ,
Galajeva J. ,
Křížová P. ,
Lucidarme J. ,
Mironov K. ,
Nurmatov Z. ,
Pana M. ,
Rahimov E. ,
Savrasova L. ,
Skoczyńska A. ,
Smith V. ,
Taha M.-K. ,
Titov L. ,
Vázquez J. ,
Yeraliyeva L.
-
a
Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
-
b
Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
-
c
University Hospital for Infectious Diseases, Zagreb, Croatia
-
d
Norwegian Institute of Public Health, Oslo, Norway
-
e
Institute for Public Health, Sombor, Serbia
-
f
Institute for Public Health, Sombor, Serbia
-
g
Eskisehir Osmangazi University, Eskisehir, Turkey
-
h
National Center for Disease Control & Public Health, Tbilisi, Georgia
-
i
National Public Health Center, Budapest, Hungary
-
j
Riga East University Hospital, Riga, Latvia
-
k
National Institute of Public Health, Prague, Czech Republic
-
l
Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
-
m
Central Research Institute of Epidemiology, Moscow, Russian Federation
-
n
Scientific and Production Association “Preventive Medicine”, Bishkek, Kyrgyzstan
-
o
Cantacuzino National Medico Military Institute for Research Development, Bucharest, Romania
-
p
Baku Medical Plaza, Baku, Azerbaijan
-
q
The Centre for Disease Prevention and Control of Latvia, Riga, Latvia
-
r
National Reference Centre for Bacterial Meningitis, National Medicines Institute, Warsaw, Poland
-
s
Meningitis Research Foundation, Bristol, United Kingdom
-
t
National Reference Centre for Meningococci, Institute Pasteur, Paris, France
-
u
Republican Research & Practical Center for Epidemiology & Microbiology, Minsk, Belarus
-
v
Institute of Health Carlos III, Madrid, Spain
-
w
Kazakh National Medical University, Almaty, Kazakhstan
Abstract
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. © 2019
Author Keywords
Index Keywords
[No Keywords available]
Link
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075339756&doi=10.1016%2fj.jinf.2019.10.018&partnerID=40&md5=6fd58248fe88456d61ef633a4d2c32b1
DOI: 10.1016/j.jinf.2019.10.018
ISSN: 01634453
Original Language: English